RMD Open. 2022 doi: 10.1136/rmdopen-2021-002165
This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.
Patients receiving ixekizumab (IXE) saw improvements in disease activity, function, and quality of life early in treatment and sustained through 116 weeks of treatment. This study is the long term extension of the COAST trial programme investing IXE in both r-axSpA and nr-axSpA patients.
In addition, treatment responses were comparable in both r-axSpA and nr-axSpA patient populations. The sustained efficacy and safety results in this selected patient population demonstrate that IXE could be a treatment option for r-axSpA and nr-axSpA. However, further confirmation is needed from real-life data.